News Home

Parry to lead rebranded RenaissanceRe Capital Partners

The division had been led by group CEO Kevin O’Donnell on an interim basis following Aditya Dutt’s departure.

Hiscox Re & ILS to grow net book in 2021 after 2020 reshaping

The firm reported a $100mn drop in ILS AuM to $1.4bn, although previously had said deployable capital was lower.

FedNat expects to cut reinsurance spend after shrinking amid broader review

The company will split out its Florida reinsurance tower and cede Uri losses to reinsurers after facing six cat events in the past year.

FedNat expects $41mn in Uri losses, reports Q4 underwriting loss driven by catastrophes

The carrier cut its policy count in Florida by 14% in the quarter, in an effort to manage exposure.

• EU antitrust regulators to warn Aon over $30bn Willis deal: Reuters
• Coca-Cola pension fund boosts ILS allocation to $362mn
• Storm Uri markdowns wipe +$220mn from Caelus, Sanders and ResRe bonds
• Genworth returns with $495mn mortgage ILS
• Booth joins Vantage in reinsurance risk role
• Universal seeks first cat bond with $100mn Cosaint Re

Opinion

When there is nothing average about cat losses, why benchmark to the mean?

ILS market enjoying spoils of post-Covid interest

Swiss Re's fund launch is a bigger ILS pivot than it may seem

Aon's new cat facility points to ILS ambitions from backers

Analysis

Armour ILS legacy funds fell to major 2019 loss before wind-down

The funds made a $93.9mn loss in 2019, ahead of a leadership changeover at legacy adviser Armour.

Texas Big Freeze: Why are the numbers so far apart?

As some in the market believe the winter claims will remain notably below $20bn, there are multiple factors creating challenges in assessing the event.

Evolving commutation practices tested by Covid and final Irma tie-up

While uncertainty over Covid may limit early commutations, isolated deals may have been struck, as 2017 contracts in some cases remain open.

Bilateral deals support sidecar growth at 1.1

One estimate suggested around $2bn of new capacity in private deals.

Supplements

(Re)Connect 2020 - ILS Roundtable

Covid-19 may have been the biggest talking point in the (re)insurance markets this year but arguably, the pandemic is being overtaken by several other factors – ILS market dynamics amongst them.

Investor Guide to ILS: H2 2020

Covid-19 and ILS strategies: locking down diversification benefits.